Rhenman & Partners Asset Management’s Abiomed Inc ABMD Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-85,900	Closed	-$21.7M	–	96
2022 Q3	$21.7M	Buy	85,900 +12,900	+18%	+$3.48M	2.27%	12
2022 Q2	$18.1M	Buy	73,000 +5,000	+7%	+$1.35M	2.05%	17
2022 Q1	$22.5M	Buy	68,000 +16,000	+31%	+$4.93M	2.22%	13
2021 Q4	$18.8M	Sell	52,000 -18,000	-26%	-$6.08M	1.25%	32
2021 Q3	$22.8M	Buy	70,000 +5,000	+8%	+$1.69M	1.6%	21
2021 Q2	$20.3M	Sell	65,000 -13,000	-17%	-$3.99M	1.38%	30
2021 Q1	$24.9M	Buy	78,000 +15,000	+24%	+$4.8M	1.73%	20
2020 Q4	$20.4M	Sell	63,000 -7,000	-10%	-$1.94M	1.67%	23
2020 Q3	$19.4M	Buy	70,000 +2,000	+3%	+$576K	1.72%	21
2020 Q2	$16.4M	Sell	68,000 -20,000	-23%	-$4.02M	1.77%	19
2020 Q1	$12.8M	Buy	88,000 +1,000	+1%	+$166K	1.79%	18
2019 Q4	$14.8M	Sell	87,000 -33,000	-28%	-$6.12M	1.63%	22
2019 Q3	$21.3M	Buy	120,000 +27,100	+29%	+$5.86M	2.68%	7
2019 Q2	$24.2M	Buy	92,900 +407	+0.4%	+$108K	2.67%	9
2019 Q1	$26.4M	Buy	92,493 +27,183	+42%	+$9.03M	3.09%	4
2018 Q4	$21.2M	Buy	65,310 +9,609	+17%	+$3.34M	2.43%	9
2018 Q3	$25.1M	Sell	55,701 -4,699	-8%	-$1.85M	2.51%	7
2018 Q2	$24.7M	Sell	60,400 -16,090	-21%	-$5.83M	2.53%	5
2018 Q1	$22.3M	Sell	76,490 -10,000	-12%	-$2.53M	2.74%	6
2017 Q4	$16.2M	Sell	86,490 -53,748	-38%	-$10M	2.19%	14
2017 Q3	$23.6M	Buy	140,238 +34,088	+32%	+$5.15M	3.02%	4
2017 Q2	$15.2M	Sell	106,150 -10,898	-9%	-$1.46M	2.18%	13
2017 Q1	$14.7M	Buy	117,048 +14,348	+14%	+$1.66M	2.32%	7
2016 Q4	$11.6M	Buy	102,700 +17,700	+21%	+$2.05M	2.22%	10
2016 Q3	$10.9M	Sell	85,000 -20,000	-19%	-$2.4M	1.74%	20
2016 Q2	$11.5M	Sell	105,000 -20,000	-16%	-$1.99M	2.04%	14
2016 Q1	$11.9M	Sell	125,000 -95,000	-43%	-$8.02M	2.35%	9
2015 Q4	$19.9M	Buy	220,000 +144,000	+189%	+$12.2M	3%	2
2015 Q3	$7.05M	Sell	76,000 -28,000	-27%	-$2.47M	1.12%	37
2015 Q2	$6.84M	Buy	104,000 +49,000	+89%	+$3.26M	0.82%	40
2015 Q1	$3.94M	Sell	55,000 -18,000	-25%	-$977K	0.66%	52
2014 Q4	$2.78M	Sell	73,000 -47,736	-40%	-$1.51M	0.81%	49
2014 Q3	$3M	Buy	120,736 +13,736	+13%	+$348K	0.88%	41
2014 Q2	$2.69M	Buy	107,000 +17,084	+19%	+$398K	0.8%	46
2014 Q1	$2.34M	Buy	89,916 +24,916	+38%	+$689K	0.7%	52
2013 Q4	$1.74M	Buy	+65,000	New	+$1.61M	0.68%	65

Other funds holding ABMD

TRSOTSOK

Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Rhenman & Partners Asset Management's ABMD Position: Q4 2022 in Review

Rhenman & Partners Asset Management sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 85,900 shares — an estimated $21.7M sold.

Rhenman & Partners Asset Management first reported a position in ABMD in Q4 2013 and held it in 36 quarters. The position peaked at $26.4M in Q1 2019. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

Rhenman & Partners Asset Management reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
Rhenman & Partners Asset Management sold 85,900 Abiomed Inc shares in Q4 2022, an estimated $21.7M.
Rhenman & Partners Asset Management first reported a position in Abiomed Inc in Q4 2013 and held it in 36 quarters.
Rhenman & Partners Asset Management's Abiomed Inc position peaked at $26.4M in Q1 2019.
8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.